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Introduction
nosis usually carries a poor prognosis with a median survival of 1-3 years from diagnosis (Christensen et al., Amyotrophic lateral sclerosis (ALS) is a neurodegenera-1990; Norris et al., 1993) and of 2-4 years from initial tive disease of the upper and lower motor neurons (Leigh weakness (Tysnes et al., 1991; Chancellor et al., 1993; and Ray-Chaudhuri, 1994) . It leads to progressive weak- Eisen et al., 1993; Haverkamp et al., 1995) . The course of ness and severe disability within a few years. The diagthe disease is reported to be slowly progressive with a linear decline of muscle strength (Munsat et al., 1988 ) and a constant risk of death (Christensen et al., 1990 ; Norris et * Corresponding author. Department of Neurophysiology and Neuroloal., 1993) . This is at odds with clinical experience that a (Mulder and Howard, 1976; Christensen et al., Participating centers (principal investigators of The Netherlands ALS Consortium): Academic Hospitals of Rotterdam (P.A. van Doorn and 1990; Norris et al., 1993) and that these patients seems to vary considerably and is considered to be difficult tö de Jong), Maastricht (C.J. Howeler and J.S.H. Vles), Groningen (A.E.J. de predict in individual cases, but how and why patients differ probably include age (Juergens et al., 1980 ; Uebayashi et consultation, adjusted for age and site of onset (Beck, al., 1983; Kondo and Hemmi, 1984; Caroscio et al., 1987; 1988) . Jablecki et al., 1989; Christensen et al., 1990; Chancellor The annual observed mortality in the study cohort was et Eisen et al., 1993; Norris et al., 1993;  compared with the usually expected mortality. The ex- Haverkamp et al., 1995) and site of onset (Mulder and pected mortality was based on mortality rates obtained Howard, 1976; Uebayashi et al., 1983; Kondo and Hemmi, from Dutch vital statistics, matched for age, sex, and 1984; Mortara et al., 1984; Caroscio et al., 1987; Christcalender period (Verheul et al., 1993) . Disease-specific ensen et al., 1990; Chancellor et al., 1993; Norris et al., excess mortality was calculated by subtracting the ex-1993).
pected mortality from the observed mortality. In order to study the mortality risk throughout the Patient characteristics subjected to univariate and multidisease and identify prognostic factors related to mortality, variate analyses were sex, age at diagnosis, site of onset, we performed a historical cohort study of untreated delay from initial weakness to diagnosis, familial or patients with ALS, who were referred to one of the sporadic type of ALS, and clinical features at diagnosis. university hospitals in The Netherlands.
The date of initial weakness was taken as the onset of the disease recognizing that fasciculations, fatigue and muscle cramps often preceded weakness and may have been the 2. Materials and methods first symptoms. The date of diagnosis was the date all initial investigations were completed and other disorders 2.1. Patients resembling ALS were excluded. Patients whose first symptoms were dysarthria or dysphagia, were considered We retrieved the hospital records of consecutive patients to have bulbar-onset ALS. who had been diagnosed as having ALS or motor neuron
The prognostic value of each specific factor was exdisease between January 1, 1970 and January 1, 1988. All pressed in terms of hazard ratio, which may be interpreted available clinical data were reviewed for confirmation of as a relative risk. The hazard ratio represents the mortality the diagnosis. Patients who fulfilled the clinical diagnostic risk per interval of time in the presence of a specific factor, criteria for probable or definite ALS (Brooks, 1994) were relative to the risk in the absence of this factor. Crude eligible for the study: upper and lower motor neuron signs; hazard ratios were estimated by univariate analyses and insidious onset and progression of weakness; involvement adjusted hazard ratios by multivariate analyses using the of at least two body regions (bulbar, cervical, thoracic, proportional hazards regression model to correct for simullumbosacral) in patients with probable ALS and at least taneously effective covariables (Cox, 1972) . All analyses three regions in those with definite ALS; no signs or were performed using the SAS Statistical Packages (SAS symptoms outside the motor system; and no other neuroInstitute, 1988). logical or systemic disorders likely to mimic the clinical syndrome (Louwerse et al., 1991; Brooks, 1994; Leigh and Ray-Chaudhuri, 1994) .
Results

Follow-up
Patients
Patients were followed-up for at least 6 years after The study cohort consisted of 307 patients, 170 males diagnosis. The primary endpoints were death from any and 137 females. We excluded 173 patients, coded under cause or chronic assisted ventilation. We obtained inthe diagnostic category of ALS or motor neuron disease, formation on the date and cause of death from the medical but who did not fulfil the clinical diagnostic criteria of records, autopsy reports, neurologists or general practitionprobable or definite ALS, including 47 patients with ers. Moreover, death was confirmed by the government progressive spinal muscular atrophy, one with progressive register.
bulbar palsy, 16 with primary lateral sclerosis, 20 with multisystem atrophy, one with a suspected post-2.3. Data analysis poliomyelitis syndrome, 17 with ALS-mimic syndromes (Louwerse et al., 1991; Brooks, 1994 ; Leigh and RayWe estimated survival from the date of diagnosis using Chaudhuri, 1994) , and 71 with various revised diagnoses, life-table methods (Kaplan and Meier, 1958) . The survival amongst others peripheral neuropathy, spinal cord or times of patients alive on January 1, 1994, were considered brainstem compression, multiple sclerosis, myopathy, and to be censored. Survival of patients unavailable for followstroke. In addition, we excluded 11 patients, because they up contributed to the estimated survival until the date of were lost to follow-up, and 58 because of uncertainty about their last follow-up visit. We imputed missing dates of both the date of diagnosis and first neurological consultadiagnosis by adding the median delay between the first tion. Finally, we excluded 30 patients who were or had neurological consultation and diagnosis to the date of first been treated with experimental drugs. The annual observed, expected, and excess mortality Mixed 31 (10) throughout the disease is shown in Fig. 1 . In the first 5
Median diagnostic delay, months (95% CI) From initial weakness 10 (9-11) years after diagnosis, mortality was mainly caused by disease-specific excess mortality. The mortality risk was at Heredity (%) its maximum in the second year after diagnosis (41% of Sporadic ALS 287 (93) population per year) and declined considerably thereafter.
Familial ALS 20 (7) Six or more years after diagnosis, the disease-specific
Values are numbers (%), means (6SD), or medians (95% CI). SD, excess mortality approached the expected mortality.
standard deviation; CI, confidence interval.
In the various subgroups of patients, similar annual mortality rates were observed, except for patients aged 40 or younger, in whom the highest mortality occurred in the The patient characteristics are shown in Table 1 . The sex fourth and fifth year after diagnosis. The greater mortality ratio differed in the various clinical variants of ALS, with a of older patients was caused by a rise in excess mortality female excess in the group presenting with bulbar symprather than by an increased expected mortality, since the toms and a male preponderance in patients below the age latter did not exceed 6% of population per year even at of 40. Half of the patients were diagnosed between 56 and advanced age. 68 years of age. Females were older at diagnosis than males, bulbar-onset patients older than those presenting with limb weakness, and sporadic cases older than familial cases, whereas age at diagnosis did not differ significantly between those with onset in the upper and lower limbs. Most frequently, patients had their initial symptoms in the limb muscles with weakness of the upper (77 patients; 25%) or lower limbs (107 patients; 35%). In 31 patients (10%), first weakness occurred simultaneously in bulbar and limb muscles. The median delay between initial weakness and ultimate diagnosis was 10 months; it was shorter for patients with bulbar onset, but did not depend on age or sex. The long delay was mainly caused by the patient himself: following the first neurological consultation, a median period of only 2 months elapsed before the ultimate diagnosis was made. In most patients, the disease was far advanced at the time of diagnosis; 215 patients (70%) had weakness of the upper limbs, 189 (61%) of the lower limbs, 166 (54%) had dysarthria, and 136 (44%) dysphagia.
Follow-up
Follow-up accumulated 938 patient years. At the com- (Table 2 , Fig. 2 ) confidence interval, 7 days to 16 months). The 24 patients (8%) who survived diagnosis 10 or more years, were all The results of univariate and multivariate analyses are males, who presented with limb weakness and were listed in Table 2 . Univariate analyses indicated that female diagnosed below the age of 40. sex, advanced age, initial weakness in bulbar or respiratory muscles, and sporadic type of the disease were associated 3.4.3. Diagnostic delay (Fig. 2d ) with shorter survival times. Multivariate analyses elimiPatients who were diagnosed within 1 year after onset of nated sex and heredity as independent risk factors. The weakness, had a shorter survival than patients in whom relatively better prognosis of males was explained by diagnosis took longer. This phenomenon was partly caused earlier and less frequently bulbar onset. The longer survivby other risk factors, especially bulbar onset that shortened al of familial cases resulted mainly from a relatively both, the time between initial weakness and diagnosis and younger age. survival after diagnosis. However, the predictive value remained present after correcting for these variables in 3.4.1. Age (Fig. 2b) multivariate analysis. Age was the most powerful predictor of survival. Prognosis gradually worsened with advancing age: patients 3.4.4. Clinical features at diagnosis who were diagnosed at an age of 40 or younger had a
Prognostic factors
In univariate and multivariate analyses, some clinical median survival of 5.0 years, compared with 1.1 year in features, if present at diagnosis, were associated with poor patients above the age of 60.
prognosis: dysarthria or dysphagia (adjusted hazard ratio 1.5; 95% confidence interval, 1.1-1.9), dyspnea at rest 3.4.2. Site of onset (Fig. 2c) (adjusted hazard ratio 1.7; 95% confidence interval, 1.1-Patients who first had bulbar symptoms tended to die 2.5), and fasciculation of spinal muscles (adjusted hazard earlier than limb-onset patients. None of the bulbar onset ratio 1.5; 95% confidence interval, 1.2-2.0). cases survived diagnosis more than 6 years. In multivariate analyses, limb onset was a predictor of survival in males only. Patients with onset of weakness in the upper and 3.5. Mortality risk groups (Table 3 ) lower limbs shared an about equal prognosis. Survival of patients with initial weakness in more than one site was
The two most powerful independent predictors of surcomparable with that of bulbar-onset patients. Patients vival, age at diagnosis and site of onset, enabled us to with initial weakness in respiratory muscles without limb identify eight subgroups of patients, each with a distinct or bulbar symptoms, had the worst prognosis with a mortality risk: (1) patients of an age of 40 or younger with median survival of only 2 months from diagnosis (95% a median survival of 5.0 years and a 5-and 10-year survival of 50 and 44%, respectively; (2) limb-onset males women with a median survival of 1.0 year and a 5-and diagnosed at an age between 40 and 60 with a median 10-year survival of 16 and 11%; (7) bulbar-onset, older survival of 3.4 years and a 5-and 10-year survival of 41 patients with a median survival of 1.0 year and a 5-and and 36%; (3) limb-onset, middle-aged females with a 10-year survival of 5 and 5%; and finally, (8) the highest median survival of 1.8 years and a 5-and 10-year survival mortality risk in patients presenting with truncal weakness of 18 and 14%; (4) bulbar-onset, middle-aged patients with with a median survival of 2 months and no patients alive 5 a median survival of 1.8 years and a 5-and 10-year years after diagnosis. The percentage of patients in the survival of 12 and 12%; (5) limb-onset men above the age various subgroups surviving 1, 2, 3, 4, 5, and 10 years after of 60 with a median survival of 1.4 years and a 5-and diagnosis in the various mortality risk groups are listed in 10-year survival of 18 and 7%; (6) limb-onset, older Table 3 . 
Values are percentages (95% CI) of patients surviving after diagnosis, median (95% CI) survival in years or number of patients; CI, confidence interval; N, number of patients. a Either age, site of onset, or sex, unless specified. b Survival after follow-up period of more than 17 years.
Discussion
ral to an academic centre or may be too ill to go there, whereas younger patients are more likely to seek a second We found that the mortality risk of patients with ALS opinion. Also, antibiotics, tube-feeding, and symptomatic did not remain constant through the disease. Mortality was treatment, are more commonly given in specialized cenat its maximum in the second year after diagnosis and tres. Therefore, patients with ALS seen in academic declined considerably thereafter. Patients who survived hospitals may have a relatively better prognosis. On the diagnosis 6 years or more, had almost the same life other hand, patients with a very mild disease progression expectancy as their healthy coevals. In addition, we may not bother to get medical care elsewhere. observed associations between mortality and age at diagThe significantly reduced survival of older patients in nosis, site of onset, and the delay from initial weakness to our study is in accordance with previous studies (Juergens diagnosis. The better prognosis of patients presenting with et al., 1980; Uebayashi et al., 1983 ; Kondo and Hemmi, limb weakness was not observed in females. 1984; Caroscio et al., 1987; Jablecki et al., 1989 ; ChristThe characteristics and survival of our study population ensen et al., 1990; Chancellor et al., 1993 ; Eisen et al., were similar to those, found in other West-European and 1993; Norris et al., 1993; Haverkamp et al., 1995) and North-American series (Mulder and Howard, 1976;  proved not to result from a rise in expected mortality only. Juergens et al., 1980; Uebayashi et al., 1983; Kondo and The mechanism, by which disease progression in ALS Hemmi, 1984; Mortara et al., 1984; Gubbay et al., 1985;  speeds up with increasing age, is unknown. However, the Chazot et al., 1986; Caroscio et al., 1987; Scarpa et al., loss of motor neurons with aging may explain why the 1988; Jablecki et al., 1989; Christensen et al., 1990;  disease has a more rapid course if the onset falls later in Chancellor et al., 1993; Eisen et al., 1993; Norris et al., life (McComas et al., 1973) . A second explanation is that 1993; Haverkamp et al., 1995) . By applying strict diagnosthe elderly may receive less intensive symptomatic care. tic criteria, we have excluded patients with diseases After correcting for age as confounding factor, we found distinct from ALS, especially with progressive spinal a better prognosis in patients with disease of limb onset, muscular atrophy who are known to have a better progbut in males only. The distinct predictive value of site of nosis (Norris et al., 1993) and possibly explain the longer onset between males and females has not been reported survivorship in studies with less strict inclusion criteria before and is yet unexplained. Bulbar patients may die (Gubbay et al., 1985; Caroscio et al., 1987) . Furthermore, earlier due to an earlier involvement of respiratory muswe preferred to study prognostic factors from the date of cles, a higher rate of respiratory complications, malnutridiagnosis, because in many patients, the onset of weakness tion, and dehydration, but this applies to both sexes. The is poorly defined and patients have a considerable recall association between site of onset and survival is still bias for it. Also, the date of diagnosis is the first oppordebated in literature. Whereas most investigators found an tunity for a neurologist to estimate prognosis, to make increased mortality in patients presenting with bulbar signs decisions about patient management, and to include paand symptoms (Mulder and Howard, 1976 ; Uebayashi et tients in clinical trials. However, we may have missed al., 1983; Kondo and Hemmi, 1984; Mortara et al., 1984 ; patients with rapidly progressive disease who died before Caroscio et al., 1987; Christensen et al., 1990; Chancellor diagnosis. et al., 1993; Norris et al., 1993) , some failed to confirm Predictions from a hospital-based study like ours may this or found no prognostic value after correcting for age have limited validity for population-based patient registers. (Juergens et al., 1980; Jablecki et al., 1989 ; Eisen et al., Rapidly deteriorating patients may not survive until refer-1993; Haverkamp et al., 1995) . The lack of unanimity may be caused by differences in symptomatic care or an delay. However, our findings do not allow for reliable imbalance in other risk factors. Moreover, in agreement predictions of survival time in individual patients. Alwith Norris et al. (1993) , we found that patients with initial though prognostic factors were identified, there is still an weakness of respiratory muscles without limb or bulbar unexplained variability within risk groups, indicating other symptoms, had the worst prognosis with a survival of only yet unknown prognostic factors. A search for these factors a few months. Conversely, patients with an unusual long remains an important task in ALS research. disease duration were all young males below the age of 40, who presented with limb weakness. Although the number of patients is small, prognostically they should be consid
